Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST.

Annals of surgery·2026
Same author

Universal healthcare: more tax, less litigation?

American journal of surgery·2026
Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026
Same author

Abortion restrictions and female medical school applicants: A retrospective study.

PLOS global public health·2026
Same author

Off the Books: A Scoping Review of the Minority Tax and Professional Advancement in Academic Surgery.

The Journal of surgical research·2026
Same author

ASO Visual Abstract: Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution.

Annals of surgical oncology·2026

Related Experiment Video

Updated: Sep 27, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.8K

Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas-Looking Forward.

Alexandra C Istl1, Alessandro Gronchi2

  • 1Division of Surgical Oncology, Johns Hopkins Hospital, Baltimore, MD 21287, USA.

Cancers
|April 12, 2022
PubMed
Summary

Neoadjuvant radiotherapy may improve outcomes for liposarcoma (LPS) patients with retroperitoneal sarcomas (RPS). However, it showed no benefit for leiomyosarcoma (LMS) or dedifferentiated LPS, highlighting the need for histology-specific treatment strategies.

Keywords:
STRASSchemotherapyneoadjuvantradiation therapyretroperitoneal sarcoma

More Related Videos

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
12:34

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

16.8K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

630

Related Experiment Videos

Last Updated: Sep 27, 2025

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

9.8K
Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction
12:34

Robot-Assisted Radical Antegrade Modular Pancreatosplenectomy Including Resection and Reconstruction of the Spleno-Mesenteric Junction

Published on: January 3, 2020

16.8K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

630

Area of Science:

  • Surgical Oncology
  • Medical Oncology
  • Radiation Oncology

Background:

  • Complete surgical resection is the primary treatment for primary retroperitoneal sarcomas (RPS).
  • Neoadjuvant treatment trials for RPS have faced enrollment challenges.
  • The STRASS trial is a significant milestone in RPS research, investigating neoadjuvant radiotherapy.

Purpose of the Study:

  • To evaluate the efficacy of neoadjuvant radiotherapy for primary resectable RPS.
  • To explore histology-specific treatment responses in RPS.
  • To identify future research directions for RPS management.

Main Methods:

  • The STRASS trial investigated neoadjuvant radiotherapy in patients with primary resectable RPS.
  • Analysis focused on abdominal recurrence-free survival as the primary endpoint.
  • Subgroup analyses examined treatment effects based on sarcoma histology (liposarcoma, leiomyosarcoma, dedifferentiated liposarcoma).

Main Results:

  • The STRASS trial did not meet its primary endpoint for overall abdominal recurrence-free survival.
  • A potential benefit of neoadjuvant radiotherapy was observed in liposarcoma (LPS) patients.
  • No significant benefit was found for leiomyosarcoma (LMS) or high-grade dedifferentiated LPS, consistent with patterns of distant failure.

Conclusions:

  • Treatment strategies for RPS should be tailored to specific histologies.
  • Neoadjuvant radiotherapy may have a role in LPS, but not in LMS or high-grade DD-LPS.
  • Future research, including the STRASS2 trial, will focus on neoadjuvant chemotherapy and novel systemic therapies for specific RPS histotypes.